Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...

A program that focuses on the mental health of a patient diagnosed with stage four breast cancer. When someone hears, you ...

Women diagnosed with advanced breast cancer appeared more likely than those with earlier-stage breast cancer to have ...

Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...

West Philadelphia native Fran Visco, who heads the National Breast Cancer Coalition, is feted at White House. When Fran Visco ...

Around 1,200 people with advanced breast cancer could benefit from a decision by NICE to give the go-ahead to a new treatment ...

Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...

Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ETCAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE ...

TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...

The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response ...

Another new year, another half-billion-biobuck transaction between Insilico Medicine and the Italian drugmaker Menarini Group ...

Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based ...